All In MedTech

FDA Clearance Tracker · P060022-S026

Akreos Posterior Chamber Intraocular Lens

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 4, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 4, 2021

Approved

Time to decision

249 days

Received Aug 28, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P060022-S026
Device name
Akreos Posterior Chamber Intraocular Lens
Applicant location
Irvine, CA
Received
Aug 28, 2020
Decided
May 4, 2021
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P060022

Device type

Device class
Class III
Regulation
21 CFR 886.3600
Specialty
Ophthalmology

Every decision under product code HQL

FDA's approval statement

As written in FDA's record.

Approval for changes to the packaging of preloaded Akreos intraocular lens models AO60 and MI60.

Source documents

Other decisions for Bausch & Lomb, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.